Correction to: Nature https://doi.org/10.1038/nature14122, published online 28 January 2015.
We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources1. The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.
Supplementary information is available in the online version of the Amendment.
References
Leroy, B. et al. Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum. Mutat. 35, 756–765 (2014).
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Information
This file contains the corrected Supplementary Table 4.
Rights and permissions
About this article
Cite this article
Fillmore, C.M., Xu, C., Desai, P.T. et al. Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 563, E27 (2018). https://doi.org/10.1038/s41586-018-0580-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-018-0580-6
This article is cited by
-
Context-specific functions of chromatin remodellers in development and disease
Nature Reviews Genetics (2023)
-
Radiosynthesis of [11C]EI1 for imaging EZH2 using positron emission tomography
Medicinal Chemistry Research (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
